Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call
WEIFANG,
Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (“Shengtai” or “the Company”),
a leading manufacturer and distributor of high-quality, pharmaceutical grade
glucose products in
results for the three months ended
market on
on
results. A question and answer session will follow management’s presentation.
Ms.
A live webcast of the conference call will be available on the Investor
Relations page of Shengtai Pharmaceutical’s web site at
http://www.shengtaipharmaceutical.com . Please visit the Web site at least 15
minutes early to register for the webcast and download any necessary audio
software.
To participate, please call the following numbers ten minutes before the
call start time:
Phone Number + 1 (877) 407-9205 (North America)
Phone Number + 1 (201) 689-8054 (International)
A replay of the call will be available through
Phone Number +1 (877) 660-6853 (North America)
Phone Number +1 (201) 612-7415 (International)
Account Number: 286
Conference ID Number: 323305
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary,
Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang
Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of
pharmaceutical grade glucose used for medical purposes. It also manufactures
and supplies glucose and cornstarch products to the food, beverage and
industrial production industries in
Forward-looking Statements
Certain statements made in this news release, may contain forward-looking
statements concerning the Company’s business and products. These statements
include, without limitation, statements regarding our ability to prepare the
Company for growth, future increases in market demand, possible increases in
our market share and predictions and guidance relating to the Company’s future
financial performance. We have based these forward-looking statements largely
on our current expectations and projections about future events and financial
trends that we believe may affect our financial condition, results of
operations, business strategy and financial needs, but they involve risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements, which may include, but are not limited to,
such factors as unanticipated changes in product demand especially in the
pharmaceutical industry, pricing and demand trends for the Company’s products,
changes to government regulations, risk associated with operation of the
Company’s new facilities, risk associated with large-scale implementation of
the Company’s business plan, the ability to attract new customers, ability to
increase our products’ applications, cost of raw materials, downturns in the
Chinese and world economy, and other information detailed from time to time in
the Company’s filings and future filings with the United States Securities and
Exchange Commission. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements herein and are cautioned not to
place undue reliance on such forward-looking statements, which are qualified
in their entirety by this cautionary statement. The forward-looking statements
made herein speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the Company’s expectations.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Ms. Yiru Melody Shi
Chief Financial Officer
Email: shengtaicfo@hotmail.com
Grayling
Eddie Cheung
Investor Relations
Tel: +1-646-284-9414
Email: eddie.cheung@us.grayling.com
SOURCE Shengtai Pharmaceutical, Inc.